GDC-0927 Racemate is primarily investigated for its potential in cancer therapy, particularly in the treatment of hormone receptor-positive breast cancer. It functions as an estrogen receptor antagonist, effectively blocking estrogen receptors to inhibit the growth of cancer cells that rely on estrogen for proliferation. This makes it a promising candidate for targeted therapy in patients whose tumors are driven by estrogen receptor signaling. Additionally, its role in preclinical studies has shown potential in overcoming resistance to other hormonal therapies, offering a new avenue for treatment in resistant or recurrent cases. Research continues to explore its efficacy and safety in clinical settings.